3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
9
fludarabine
7
Standard of Care
5
Mycophenolic Acid
5
Whole-Body Irradiation
4
Specimen Handling
4
Sirolimus
4
Mesna
4
Filgrastim
4
Practice Guidelines as Topic
3
Nivolumab
3
Melphalan
3
GSK2636771
3
venetoclax
2
trametinib
2
talquetamab
2
osimertinib
2
dabrafenib
2
X-Rays
2
Thiotepa
2
Tacrolimus
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
Busulfan
2
Biopsy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
thymoglobulin
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
ARQ531
×
30 days
×
Clear all
NCT04728893
2026-06-12
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled